Stocks To Buy Forum

Stocks to Buy based on the Best Stock Market Research

John James
  • Male
  • Frankfurt
  • Germany
Share

John James's Discussions

TNXP (MC $32M) (Cash $34M) O/S 7.5 M / P3 Data in 1H 2018 =potential 10 bagger

Found another terrible undervalued which trading below Cash and which is close to phase 3 readout if successfull the drug will have around $600+ M Market Potential . The Company has only 7.5 Million…Continue

Started Oct 3

MDNA.TO (MC C$36 M) (Cash C$20 M) Positvie Results in Q1 could lead to FDA approval
1 Reply

MDNA.TO (MC C$36 M) (Cash C$20 M) Hot Cancer Play with important Results in Q1 that could lead to FDA approval =1500-2000% UPSIDE Potential ! Brutally cheap and completely unknown canadian biotech…Continue

Started this discussion. Last reply by John James Sep 21.

SNOA (MC $23 M) (Cash $13 M) Lots of Marketed Products + New Launches soon
3 Replies

SNOA (MC $23 M)(Cash $13 M) Shares Out 4.3 M / Lots of Marketed Products some of them are in early launch phase plus additional Product launches expected within 6 months / Revenue close to hit $16…Continue

Started this discussion. Last reply by John James Oct 31.

KTOV (MC $16 M) (Cash $17 M) US-NDA Submission for Big Drug this Quarter
2 Replies

another super hot and dirt cheap FDA playKTOV (MC $16 M) (Cash $17 M) US-NDA Submission for their osteoarthritis pain and hypertension drug exptected this Quarter. This ultra low float stock will be…Continue

Started this discussion. Last reply by John James Oct 9.

 

John James's Page

Latest Activity

John James replied to John James's discussion SNOA (MC $23 M) (Cash $13 M) Lots of Marketed Products + New Launches soon
"Great News out today ...Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Productshttps://finance.yahoo.com/news/sonoma-pharmaceuticals-receives-brazilian-approvals-114500685.html"
Oct 31
John James replied to John James's discussion SNOA (MC $23 M) (Cash $13 M) Lots of Marketed Products + New Launches soon
"This ultra low float stock is brutally undervalued which tradingjust a few pennies above Book Value .Fantastic entry point here this stock is definitely one of the cheapest in the Pharma Sector .GL Sonoma Pharma (Nasdaq: SNOA) Marketcap: 19.6…"
Oct 18
John James replied to John James's discussion KTOV (MC $16 M) (Cash $17 M) US-NDA Submission for Big Drug this Quarter
"KTOV (Market Cap $20 M ) (Cash $11 M) FDA Decision in Q2 + Phase 3 Results this Q / Shares Out: 10.6 M = HUGE Upside Potential here Kitov Phama (KTOV)Market Cap $20 MiillionCash $11 MillionPrice: 1.94Shares Out 10.6 MillionKitov Announces FDA…"
Oct 9
John James posted a discussion

TNXP (MC $32M) (Cash $34M) O/S 7.5 M / P3 Data in 1H 2018 =potential 10 bagger

Found another terrible undervalued which trading below Cash and which is close to phase 3 readout if successfull the drug will have around $600+ M Market Potential . The Company has only 7.5 Million Shares outstanding and Baker bros who are really one of the most successful investors in the Biotech Sector is second largest staekholder . TNXP should be valued right now around $15 per share for their Phase 3 program and huge cash balance and if phase 3 outcome is positive then sky is the limit…See More
Oct 3
John James replied to John James's discussion MDNA.TO (MC C$36 M) (Cash C$20 M) Positvie Results in Q1 could lead to FDA approval
"Nice move yesterdaySmall Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the…"
Sep 21
John James posted a discussion

MDNA.TO (MC C$36 M) (Cash C$20 M) Positvie Results in Q1 could lead to FDA approval

MDNA.TO (MC C$36 M) (Cash C$20 M) Hot Cancer Play with important Results in Q1 that could lead to FDA approval =1500-2000% UPSIDE Potential ! Brutally cheap and completely unknown canadian biotech stock with minimum 10 bagger potential . Positive Phase 2 results in recurrent glioblastoma which expected in Q1 2018 could lead to accelerated approval which would be a HUGE MAJOR milestones for this undiscovered low float stock . This company has brutally low valuation of only $36 million and most…See More
Sep 20
John James replied to John James's discussion SNOA (MC $23 M) (Cash $13 M) Lots of Marketed Products + New Launches soon
"New Fact Sheet ....http://files.shareholder.com/downloads/OCLS/4978439479x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdfØ Pure play dermatology-focused company, building multi-technology platformØ Products based on…"
Aug 24
John James posted a discussion

SNOA (MC $23 M) (Cash $13 M) Lots of Marketed Products + New Launches soon

SNOA (MC $23 M)(Cash $13 M) Shares Out 4.3 M / Lots of Marketed Products some of them are in early launch phase plus additional Product launches expected within 6 months / Revenue close to hit $16 million/Profitability expected in 2018 . This undiscovered and revenue generating company is one if not the cheapest pharma you can get at this time .This Stock looking fantastic on all fronts it has a terrible low valuation of $23 Million is well financed with around $13 million and has a ultra low…See More
Aug 14
John James replied to John James's discussion KTOV (MC $16 M) (Cash $17 M) US-NDA Submission for Big Drug this Quarter
"An older article but nice one which shows the massive potential here https://seekingalpha.com/article/3939596-kitov-pharmaceuticals-bullish-valuation-based-comparablesConclusionIn my original article, I ballparked KTOV's valuation at $22.50 per…"
Jul 19
John James posted a discussion

KTOV (MC $16 M) (Cash $17 M) US-NDA Submission for Big Drug this Quarter

another super hot and dirt cheap FDA playKTOV (MC $16 M) (Cash $17 M) US-NDA Submission for their osteoarthritis pain and hypertension drug exptected this Quarter. This ultra low float stock will be one of the hottest and most underpriced FDA play i ever have seen in last 20 years in stock trading. KTOV has really more than 10 bagger potential the stock is trading at cash level and the valuation is ONLY $16 Million i cant believe it but please do your own dd and realize the brutal potential…See More
Jul 19
John James replied to John James's discussion ACRX (MC $97 M) Cash $72 M / FDA Decision on Oct 12 / P3 results this month
"Nice jump in Pre-Mkt and we are just days away before phase 3 results will be released and 3 months before FDA decision so there is good chance for a run close or maybe even over $10 .GL Upcoming Major Milestones Zalviso Phase 3 Results in July…"
Jul 17
John James posted a discussion

ACRX (MC $97 M) Cash $72 M / FDA Decision on Oct 12 / P3 results this month

FDA Decision in October for potential Blockbuster and Phase 3 readout this month for another Drug = SUPER HOT AND DIRRT CHEAP FDA GEM ACRX (MC $97 M) Cash $72 M / FDA Decision on Oct 12 / P3 results this month...Im in as well guys love it . Very attractive and dirt cheap FDA Play ..... ACRX has 2 Products including potential Blockbuster under review by FDA and MAA (Europe) . Upcoming Milestones : Zalviso (Pain) final Phase 3 results this month // DSUVIA (Pain) with FDA Decision on October…See More
Jul 14
John James replied to John James's discussion IGXT (MC $32 M) 2 FDA approvals coming + 2 New NDA Submissions in 4Q = 10+ BAGGER EASILY
"Heavily undervalued stock with so many big milestones on the way , could be hottest and cheapest FDA play for the next 9-12 months . This Stock could run to $3+ before FDA decision .GL Market cap $55 million Upcoming Milestones: NDA submission…"
Jun 23
Stocks To Buy replied to John James's discussion AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 in various indication ongoing =TOP PICK
"Jumping today, nice stock pick!"
Jun 20
John James replied to John James's discussion AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 in various indication ongoing =TOP PICK
"Nice price jump looks like its on the way to break the size back the MA(200) at $5.54 .With positive phase 3 results in the coming weeks this low float stock will jump close or even above $10 ."
Jun 20
John James replied to John James's discussion AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 in various indication ongoing =TOP PICK
"Nice move today ,, Start Phase 2/3 of Alzheimer agitation trial within days...... Nice move today ,, Start Phase 2/3 of Alzheimer agitation trial within days......Nice move today ,, Start Phase 2/3 of Alzheimer agitation trial within days ..."
Jun 6

Comment Wall

You need to be a member of Stocks To Buy Forum to add comments!

Join Stocks To Buy Forum

  • No comments yet!
 
 
 

Stocks to Buy 2017

Stocks to Buy 2017

Small Cap Bull 3x (TNA)
Shake Shack (SHAK)
Stocks to Watch - 2018
Penny Stocks - 2018



Twitter - Free Stock Alerts

© 2017   Created by Stocks To Buy.   Powered by

Badges  |  Report an Issue  |  Terms of Service